Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test whether SU011248 has activity and is safe in patients with metastatic non-small cell lung cancer (NSCLC) who have failed a platinum-containing regimen and docetaxel.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Sunitinib

Criteria

Inclusion Criteria:

• Histologically confirmed advanced or metastatic Non-Small Cell Lung Cancer that cannot be cured with surgery, radiation, or combination thereof

• No more than 2 prior chemotherapy treatments including treatment with a platinum containing therapy

• Evidence of measurable disease by radiographic technique

• Male or Female, 18 years or older

• ECOG performance status of 0 or 1

• Resolution of all acute toxicities of prior therapies

• Adequate organ function

Exclusion Criteria:

• Major surgery or radiation therapy within 4 weeks

• Severe hemorrhage within 4 weeks

• Previous treatment with anti-angiogenesis agents

• Diagnosis of second malignancy within last five 5 years

• History of or known brain metastases, spinal cord compression, or carcinomatous meningitis

• Known HIV

• Serious acute or chronic illness

• Current treatment on another clinical trial

• Pregnant or breastfeeding